Meitheal Pharmaceuticals Inc. secured FDA approval for its intravenous Daptomycin, positioning the company to capitalize on the high-value antibiotic market and potentially capture significant share as a generic alternative.
Meitheal Pharmaceuticals Inc. secured FDA approval for its intravenous Daptomycin, positioning the company to capitalize on the high-value antibiotic market and potentially capture significant share as a generic alternative.